Brendan Horton

Brendan Horton has gained extensive research experience specializing in cancer biology. Brendan earned their undergraduate degree from Boston University, where they conducted senior thesis research and created a lymphoma cell line expressing the activator of NF-kB signaling. At the University of Chicago, they pursued their PhD in Cancer Biology and studied the mechanisms of tumor-infiltrating T cell reactivation for cancer treatment using monoclonal antibodies directed against immunological targets. From 2017 to 2023, they served as a Postdoctoral Researcher at the Massachusetts Institute of Technology, where they conducted cancer research. In 2023, they secured a Scientist II position with Ankyra Therapeutics.

Brendan Horton obtained a B.A. in Biochemistry and Molecular Biology from Boston University in 2009. Brendan went on to pursue a PhD in Cancer Biology at the University of Chicago, where they studied from 2009 to 2017.